Immuron Ltd — Capital/Financing Update 2013

Apr 29, 2013

==> picture [199 x 43] intentionally omitted <==

ASX Announcement / Media Release

Tuesday 30[th] April 2013

Renounceable Pro-Rata Rights Issue – Closure, Acceptances and Shortfall

Immuron Limited [ASX: IMC] (the Company) hereby advises that the recent renounceable rights issue offer made pursuant to the Prospectus dated 27 March 2013 to raise approximately $1.9 million (before expenses) on the basis of three (3) new fully paid shares in the Company (Share) for every two (2) fully paid Shares held at an issue price of 0.3 cents ($0.003) (the Rights Issue), closed on 29[th] April 2013.

The Company advises that it has received entitlement acceptances in respect of 88,641,762 shares. Eligible Shareholders also subscribed for a further 5,997,082 in additional oversubscribed new shares under the shortfall available. The total funds received from Shareholders totalled $283,917.

This provides a remaining shortfall of 526,631,242 shares.

As the Rights Issue was fully underwritten by Patersons Securities Limited (the Underwriter). In accordance with the terms of the underwriting agreement, the Company has issued a shortfall notice to the Underwriter for the remaining 526,631,242 shortfall shares, amounting to $1,579,894.

For and on behalf of the Board,

Kind Regards;

==> picture [105 x 40] intentionally omitted <==

Peter Vaughan Company Secretary Immuron Limited

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. Immuron has one product on the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Centre (Israel), the University of Melbourne and Monash University (Australia).

Level 1 18 Kavanagh Street Southbank, Vic 3006

www.immuron.com

Phone: + 61 (0)3 8648 4530 Facsimile: + 61 (0)3 9686 9460

ABN: 80 063 114 045